Evogene (EVGN) investor relations material

Executive summary

• Underwent a major transformation into a lean, AI-driven computational chemistry company focused on pharma and crop protection, with ChemPass as the core platform and workforce reduced from 117 to 38 over 18 months.

• Established six active drug development collaborations and advanced internal drug discovery and crop protection programs.

• Monetized non-core assets, including the sale of Lavie Bio and licensing of Biomica's phase I asset, and realigned Casterra to focus on Brazil.

• Board faces a challenge from dissident shareholders but emphasizes continuity and plans to add two new industry experts.

• Expanded ChemPass AI platform, integrating advanced AI agents and increasing virtual chemical space to 110 billion molecules.

Financial highlights

• Consolidated cash and equivalents at June 30, 2026: $9.3 million; Q2 cash usage: $2.1 million.

• Q2 2026 net loss: $1.8 million, down from $4.7 million in Q2 2025 and $6 million in Q2 2024.

• H1 2026 revenues: $0.7 million, down from $2.9 million in H1 2025, mainly due to lower Casterra sales.

• R&D expenses for H1 2026: $2.9 million, down from $3.5 million in H1 2025; Q2 2026 R&D expenses: $1.4 million, down from $1.7 million in Q2 2025.

• H1 2026 net loss: $7.7 million, unchanged from H1 2025.

Outlook and guidance

• Full-year 2026 cash usage expected at $8.5–$9.5 million, with further reductions anticipated in 2027.

• Focus on progressing pharma and ag research collaborations, securing new partnerships, and advancing internal programs.

• Plans to increase investor outreach and IR activities as operational results become more tangible.